Navigation Links
As a Result of the FDA Investigation Into TNF-Alpha Inhibitors, 30 Percent of Surveyed Rheumatologists Have Altered Their Prescription Patterns for Juvenile Idiopathic Arthritis
Date:3/26/2009

Twenty Percent of Surveyed MCO Pharmacy Directors Say They Will Alter Reimbursement of TNF-alpha Inhibitors for Juvenile Idiopathic Arthritis and Pediatric Crohn's Disease, According to a New Report from Decision Resources

WALTHAM, Mass., March 26 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that 30 percent of surveyed rheumatologists have altered their prescription patterns for juvenile idiopathic arthritis and more than 10 percent have altered their prescription patterns for adult rheumatoid arthritis in response to the Food and Drug Administration's (FDA) investigation into the malignancy risk associated with TNF-alpha inhibitors.

In June 2008, the FDA launched an investigation into the malignancy risk associated with TNF-alpha inhibitors in pediatric and juvenile populations being treated for autoimmune diseases. Concerns were raised when 30 cases of cancer in pediatric and juvenile patients being treated for rheumatoid arthritis and Crohn's disease were reported between 1998 and 2008.

The new Physician & Payer Forum report entitled TNF-alpha Inhibitors in Pediatric Crohn's Disease and Juvenile Idiopathic Arthritis: How Will Physicians and Payers Balance Effective Treatments and Serious Safety Concerns? finds that, of the rheumatologists that have altered their prescription patterns for juvenile idiopathic arthritis, 71 percent say that they prescribe conventional disease-modifying antirheumatic drugs more frequently than they had in the past. Nearly 60 percent of surveyed gastroenterologists say they have altered their prescription patterns for pediatric Crohn's disease -- of these gastroenterologists, 42 percent indicate that they restrict TNF-alpha inhibitors to patients with more severe disease. Furthermore, 45 percent of gastroenterologists say that they have altered their prescribing habits in a
'/>"/>

SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Cowden Associates Releases Eighth-Annual Employee Benefit Survey Results
2. China Medicine Announces Record Fourth Quarter and 2008 Results
3. Londons First Science-Based Cellulite Massage Guarantees Results for Londons Cellulite Sufferers
4. Boys Skin Care Range Finds Interesting Results
5. Surgical Care Affiliates Announces Investor Conference Call to Discuss 2008 Fourth Quarter and Year-End Results
6. Subtle Fillers Bring Breathtaking Results; The Neigel Center for Cosmetic and Laser Surgery Hosts Its March 27th Filler Day Specials!
7. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Fourth Quarter and Year Ended December 31, 2008 and to Provide a Business Update
8. Global Med Technologies(R), Inc. to Report Fourth Quarter and Year End Financial Results Today
9. Discovery may result in new test to determine predisposition to cancer
10. Cord Blood America Announces Results of Shareholder Special Meeting
11. Why Are Healthcare Information Manufacturers Free of All Liability When Their Products Can Result in Medical Errors?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2015)... 28, 2015 OsteoRemedies®, LLC, Memphis, ... two-stage revision of infected hip and knee arthroplasty. ... as a pre-formed, pre-loaded spacer with Gentamicin Antibiotics, ... joint space. Combined with a consistent process ... spacer is approved for temporary use for up ...
(Date:4/28/2015)... CA (PRWEB) April 28, 2015 Once considered ... Grow Lights have taken the industry by storm with perfectly ... to use unit. , More than half of ... KIND LED , proving the stigma is gone and ... The overwhelming positive response from customers and their first hand ...
(Date:4/28/2015)... 2015 Jovium®, a brand focused on ... better emotional balance, has begun to increase its market ... scale to enhance their mood and relieve some of ... Jovium® System aims to help patients overcome some of ... through all-natural products that do not cause or carry ...
(Date:4/28/2015)... NV (PRWEB) April 28, 2015 According ... Center for Ethics (June 27, 2014), prescription drugs ... world. Medical Science is becoming increasingly aware of the ... the market, such as chemotherapy drugs to treat cancer, ... that are quickly evolving to become increasingly resistant to ...
(Date:4/28/2015)... Foot and Ankle Specialists of ... Palmer ( Annapolis and Clarksville Divisions ) was ... the Maryland Podiatric Medical Association meeting on April 15, ... in 1992 with a Bachelor of Arts in Life ... intercollegiate soccer, track and cross-country. He then attended the ...
Breaking Medicine News(10 mins):Health News:SuperCloset Reports Surge in KIND LED Grow Light Sales, Saving Indoor Growing Enthusiasts up to 40% on their Power Usage. 2Health News:Jovium® Products Help Customers to Achieve Emotional Balance 2Health News:Trivedi Science™ Announces the Beginning of Their Science Research to Create Highly Effective Pharmaceutical Drugs with Minimal Side Effects 2Health News:Trivedi Science™ Announces the Beginning of Their Science Research to Create Highly Effective Pharmaceutical Drugs with Minimal Side Effects 3Health News:Trivedi Science™ Announces the Beginning of Their Science Research to Create Highly Effective Pharmaceutical Drugs with Minimal Side Effects 4Health News:Foot and Ankle Specialists of the Mid-Atlantic, LLC Podiatrist Receives Maryland Podiatric Medical Association Outstanding Service Award 2
... , , CUPERTINO, Calif., July ... that Matthew Hogan, Chief Financial Officer, will be presenting at the ... August 5 at 4:00 pm Eastern Time. The conference is ... A webcast of the presentation will be accessible at: ...
... , WASHINGTON, July 28 The ... House of Representatives, goal of expanding health coverage to a ... the Society urges the House to make significant revisions to ... care its first priority and protect patient access to specialists. ...
... FRANKLIN LAKES, N.J., July 28 The Board of Directors ... a quarterly dividend of 33 cents per common share, payable on September ... annual dividend rate is $1.32 per share. , , ... technology company that develops, manufactures and sells medical devices, instrument systems and ...
... , MORRISTOWN, N.J., July 28 Watson Pharmaceuticals, ... and specialty branded pharmaceuticals, today announced a license agreement with ... generic version of Ferrlecit (sodium ferric gluconate complex in sucrose ... anemia in hemodialysis patients receiving supplemental epoetin therapy. , ...
... , , Hoag Hospital recognized ... providing optimal level care to breastfeeding mothers and infants , ... Memorial Hospital Presbyterian announced today its designation as a certified Baby-Friendly ... World Health Organization (WHO) and the United Nations Children,s Fund (UNICEF). ...
... PHILADELPHIA Cancer researchers are turning to mathematical models ... paper in Cancer Research , a journal of ... technique may answer questions about Herceptin resistance. ... Oncology Program at the University of Michigan Comprehensive Cancer ...
Cached Medicine News:Health News:DURECT to Present at the BMO Capital Markets Healthcare Conference 2Health News:SCAI Opposes U.S. House of Representatives Health Reform Bill in Current Form 2Health News:SCAI Opposes U.S. House of Representatives Health Reform Bill in Current Form 3Health News:Watson Announces License Agreement With GeneraMedix for Generic Version of Ferrlecit(R) 2Health News:Hoag Hospital Certified as Baby-Friendly Facility 2Health News:Hoag Hospital Certified as Baby-Friendly Facility 3Health News:Mathematical modeling predicts response to Herceptin 2
(Date:4/28/2015)... N.J. , April 28, 2015 As ... Stryker Orthopaedics, is kicking off tournament week by heading ... second consecutive year appearing at the tournament, Stryker continues ... about the importance of joint health and mobility. As ... , Stryker is bringing new features to enhance ...
(Date:4/28/2015)... April 28, 2015   HX360 today ... of the inaugural HX360 Innovation Challenge ... improved patient experience in hospital and health system ... original field of eighty-three entries, with the four ... panel during the HX360 Innovation Challenge program at ...
(Date:4/28/2015)... -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) ... I am very excited to announce that we ... clinical trial for oral insulin (ORMD-0801) and the treatment of ... in the coming weeks. This clinical trial will be our largest ... milestone for the company, literally putting us in a different ...
Breaking Medicine Technology:The Stryker Mobility Zone Heads to Insperity Invitational for Second Consecutive Year 2The Stryker Mobility Zone Heads to Insperity Invitational for Second Consecutive Year 3The Stryker Mobility Zone Heads to Insperity Invitational for Second Consecutive Year 4Ginger.io And WiserCare Named Winners Of The HX360 Innovation Challenge 2Ginger.io And WiserCare Named Winners Of The HX360 Innovation Challenge 3Oramed Pharmaceuticals Inc. Issues Phase IIb Study Update Letter 2Oramed Pharmaceuticals Inc. Issues Phase IIb Study Update Letter 3
... Aug. 2 Cytokine PharmaSciences,Inc. (CPSI) today ... inhibitors showed oral efficacy in animal models. ... it is advancing one of these compounds,into ... or MIF, is linked to many,conditions, including ...
... ARBOR, Mich., Aug. 3 Far more of today,s,heart attack ... clogged heart arteries than even a,decade ago, a new study ... from this urgent treatment,-- which is known to save lives ... it at all, the study shows. And the chance ...
Cached Medicine Technology:Cytokine Demonstrates Oral Efficacy of Small-Molecule MIF Inhibitors 2Many Heart Attack Patients Don't Get Best Emergency Treatment 2Many Heart Attack Patients Don't Get Best Emergency Treatment 3Many Heart Attack Patients Don't Get Best Emergency Treatment 4
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: